Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade

Abstract

Salvicine is a new diterpenoid quinone substance from a natural source, specifically in a Chinese herb. It has powerful growth-controlling abilities against a broad range of human cancer cells in both in vitro and in vivo environments. A significant inhibitory effect of salvicine on multidrug-resistant (MDR) cells has also been discovered. Several research studies have examined the activities of salvicine on topoisomerase II (Topo II) by inducing reactive oxygen species (ROS) signaling. As opposed to the well-known Topo II toxin etoposide, salvicine mostly decreases the catalytic activity with a negligible DNA breakage effect, as revealed by several enzymatic experiments. Interestingly, salvicine dramatically reduces lung metastatic formation in the MDA-MB-435 orthotopic lung cancer cell line. Recent investigations have established that salvicine is a new non-intercalative Topo II toxin by interacting with the ATPase domains, increasing DNA–Topo II interaction, and suppressing DNA relegation and ATP hydrolysis. In addition, investigations have revealed that salvicine-induced ROS play a critical role in the anticancer-mediated signaling pathway, involving Topo II suppression, DNA damage, overcoming multidrug resistance, and tumor cell adhesion suppression, among other things. In the current study, we demonstrate the role of salvicine in regulating the ROS signaling pathway and the DNA damage response (DDR) in suppressing the progression of cancer cells. We depict the mechanism of action of salvicine in suppressing the DNA–Topo II complex through ROS induction along with a brief discussion of the anticancer perspective of salvicine.

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

“…All molecular dynamic simulation screenshots were generated using the premium YASARA software. According to the trajectory performance, the RMSD, RMSF, protein-ligand contacts (P-L), and the hydrogen bond interactions were conducted to measure whether or not the complex structure of protein and ligand could be maintained over time [ 112 , 113 ].…”

Exploring the anti‐cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review

“… 37–40 For example, anti‐cancer compounds from Curcuma longa , Piper longum , Nigella sativa , Murrayakoenigii , Amora rohituka , Withania somnifera , and Dimocarpus longan possess anti‐cancer activity against various cancers, especially anti‐BC properties 8,25,36,41–44 . Latter specific phytochemicals have been identified as a new source of anti‐cancer agents from plant extract to decrease the negative effects of cancer chemotherapies in recent research 45–48 . These natural agents can target several BC‐related pathways and provide protective activity against breast malignancies, which play a significant role in preventing and managing patients with BC 46,49 .…”

The efficacy of natural bioactive compounds against prostate cancer: Molecular targets and synergistic activities

“…Traditional herbal products and bioactive compounds are gaining popularity for cancer prevention and/or therapy due to their potential effectiveness and minimal toxicity to normal tissue (Abd El‐Ghffar et al, 2017; El‐Shawi et al, 2023; Ishaq et al, 2022). Consequently, there is a significant deal of interest in discovering novel compounds that are active against PCa and understanding the mechanisms of action of these compounds so that their qualities may be used to produce new therapeutic or preventative therapies (Choudhari et al, 2019; Biswas, Hany Rumi, et al, 2022; Dey et al, 2022). The majority of chemotherapy drugs used to treat PCa over the past four decades are derived from herbs; Moreover, isolated compounds from herbal plants are presently being investigated to provide different lead structures, which can be used as frameworks to make new and more potent anticancer drugs (Abdelghffar et al, 2021; Mann, 2002).…”